Literature DB >> 10779382

Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

T Ishizaki1, M Uehata, I Tamechika, J Keel, K Nonomura, M Maekawa, S Narumiya.   

Abstract

Y-27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide++ + dihydrochloride] is widely used as a specific inhibitor of the Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) family of protein kinases. This study examined the inhibition mechanism and profile of actions of Y-27632 and a related compound, Y-30141 [(+)-(R)-trans- 4-(1-aminoethyl)-N-(1H-pyrrolo[2, 3-b]pyridin-4-yl)cyclohexan-ecarboxamide dihydrochloride]. Y-27632 and Y-30141 inhibited the kinase activity of both ROCK-I and ROCK-II in vitro, and this inhibition was reversed by ATP in a competitive manner. This suggests that these compounds inhibit the kinases by binding to the catalytic site. Their affinities for ROCK kinases as determined by K(i) values were at least 20 to 30 times higher than those for two other Rho effector kinases, citron kinase and protein kinase PKN. [(3)H]Y-30141 was taken up by cells in a temperature- and time-dependent and saturable manner, and this uptake was competed with unlabeled Y-27632. No concentrated accumulation was found, suggesting that the uptake is a carrier-mediated facilitated diffusion. Y-27632 abolished stress fibers in Swiss 3T3 cells at 10 microM, but the G(1)-S phase transition of the cell cycle and cytokinesis were little affected at this concentration. Y-30141 was 10 times more potent than Y-27632 in inhibiting the kinase activity and stress fiber formation, and it caused significant delay in the G(1)-S transition and inhibition of cytokinesis at 10 microM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779382

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  314 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  RhoA/Rho-kinase, vascular changes, and hypertension.

Authors:  K Chitaley; D Weber; R C Webb
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 3.  Intracellular signalling involved in modulating human endothelial barrier function.

Authors:  Victor W M van Hinsbergh; Geerten P van Nieuw Amerongen
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

4.  Rho family GTP binding proteins are involved in the regulatory volume decrease process in NIH3T3 mouse fibroblasts.

Authors:  Stine F Pedersen; Kristine H Beisner; Charlotte Hougaard; Berthe M Willumsen; Ian H Lambert; Else K Hoffmann
Journal:  J Physiol       Date:  2002-06-15       Impact factor: 5.182

5.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

6.  Rho mediates the shear-enhancement of endothelial cell migration and traction force generation.

Authors:  Yan-Ting Shiu; Song Li; William A Marganski; Shunichi Usami; Martin A Schwartz; Yu-Li Wang; Micah Dembo; Shu Chien
Journal:  Biophys J       Date:  2004-04       Impact factor: 4.033

Review 7.  PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.

Authors:  Zhou-shen Zhao; Ed Manser
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

8.  Arp2/3 Complex Is Required for Macrophage Integrin Functions but Is Dispensable for FcR Phagocytosis and In Vivo Motility.

Authors:  Jeremy D Rotty; Hailey E Brighton; Stephanie L Craig; Sreeja B Asokan; Ning Cheng; Jenny P Ting; James E Bear
Journal:  Dev Cell       Date:  2017-08-31       Impact factor: 12.270

9.  Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle.

Authors:  Alexandra Wibberley; Zunxuan Chen; Erding Hu; J Paul Hieble; Timothy D Westfall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  Hypoxia-reoxygenation-induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase.

Authors:  Muhammad Aslam; Klaus-Dieter Schluter; Susanne Rohrbach; Amir Rafiq; Sabiha Nazli; Hans Michael Piper; Thomas Noll; Rainer Schulz; Dursun Gündüz
Journal:  J Physiol       Date:  2012-10-22       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.